Meanwhile, there is clinical evidence that MCP-1, which reflects the inflammatory response in patients with AMI complicated by CS, is strongly expressed in the early phase (0–4 h), and has prognostic value in assessing the clinical outcomes [17,18]. The gene discussed is CCL2; the disease is Cowden syndrome 1.